# Case Study 1: Theranos - A Governance Failure

## Module 24: Corporate Governance

---

## Navigation

[← Module Overview](../README.md) | [Case 2: Activist Investor →](case-02-activist-investor.md)

---

## Learning Objectives

By analyzing this case, you will be able to:

1. **Identify** the governance failures that enabled fraud at Theranos
2. **Analyze** the role of board composition and expertise
3. **Evaluate** the importance of skeptical inquiry and oversight
4. **Apply** lessons to strengthen corporate governance practices
5. **Recognize** warning signs of governance dysfunction

---

## Case Overview

```
╔═══════════════════════════════════════════════════════════════════════════╗
║                    THERANOS: CASE SUMMARY                                  ║
╠═══════════════════════════════════════════════════════════════════════════╣
║                                                                           ║
║   Company:        Theranos, Inc.                                          ║
║   Industry:       Healthcare / Medical Devices                            ║
║   Founded:        2003 by Elizabeth Holmes (age 19)                       ║
║   Peak Valuation: $9 billion (2014)                                       ║
║   Employees:      ~800 at peak                                            ║
║   Outcome:        Bankruptcy (2018), Criminal convictions (2022)          ║
║                                                                           ║
║   Core Technology Claim:                                                  ║
║   Blood testing from a single finger prick using proprietary "Edison"     ║
║   device - faster, cheaper, and more accurate than traditional testing    ║
║                                                                           ║
║   Reality:                                                                ║
║   Technology never worked as claimed; company ran most tests on           ║
║   standard machines; falsified results; endangered patients               ║
║                                                                           ║
╚═══════════════════════════════════════════════════════════════════════════╝
```

---

## The Theranos Story

### Timeline of Key Events

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    THERANOS TIMELINE                                    │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   2003 ─── Elizabeth Holmes drops out of Stanford, founds Theranos     │
│            (originally "Real-Time Cures")                               │
│                                                                         │
│   2004 ─── Raises initial funding; begins developing technology        │
│                                                                         │
│   2010 ─── Raises $45M from investors including Draper Fisher          │
│                                                                         │
│   2011 ─── Board restructured; prominent names added                   │
│            Sunny Balwani joins as COO (Holmes' boyfriend)              │
│                                                                         │
│   2013 ─── Partnership with Walgreens announced                        │
│            $100M+ raised from investors                                 │
│                                                                         │
│   2014 ─── Valued at $9 billion                                        │
│            Holmes featured on magazine covers; celebrity status         │
│            Walgreens wellness centers launch with Theranos testing      │
│                                                                         │
│   2015 ─── WSJ investigation by John Carreyrou exposes problems        │
│            October: First article questions technology claims           │
│            FDA finds serious problems with Edison device                 │
│            CMS (Medicare) begins inspection                              │
│                                                                         │
│   2016 ─── CMS issues sanctions, revokes lab license                   │
│            Walgreens terminates partnership, sues                       │
│            Holmes banned from owning/operating labs for 2 years        │
│            Voids two years of test results                              │
│                                                                         │
│   2017 ─── Settles with investors; agrees to relinquish voting control │
│                                                                         │
│   2018 ─── SEC charges Holmes and Balwani with fraud                   │
│            Holmes settles; Theranos files for bankruptcy                │
│            Federal criminal indictment                                  │
│                                                                         │
│   2022 ─── Holmes convicted of fraud (4 counts)                        │
│            Sentenced to 11+ years in prison                             │
│            Balwani convicted on all 12 counts                           │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

---

## The Board of Directors

### Board Composition Analysis

Theranos' board was notable for its composition - filled with prominent names but lacking relevant expertise.

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    THERANOS BOARD COMPOSITION                           │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   BOARD MEMBERS (At Peak):                                              │
│                                                                         │
│   POLITICAL/MILITARY:                                                   │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • George Shultz - Former Secretary of State                     │  │
│   │ • Henry Kissinger - Former Secretary of State                   │  │
│   │ • William Perry - Former Secretary of Defense                   │  │
│   │ • James Mattis - Retired Marine General (later Sec of Defense)  │  │
│   │ • Sam Nunn - Former U.S. Senator                                │  │
│   │ • Gary Roughead - Retired Admiral, Chief of Naval Operations    │  │
│   │ • Richard Kovacevich - Former Wells Fargo CEO                   │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   HEALTHCARE/SCIENCE EXPERTISE:                                         │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • William Foege - Former CDC Director (epidemiologist)          │  │
│   │                                                                 │  │
│   │ Notable ABSENCE of:                                             │  │
│   │ ✗ Laboratory medicine experts                                   │  │
│   │ ✗ Diagnostic industry executives                                │  │
│   │ ✗ Medical device regulatory experts                             │  │
│   │ ✗ Healthcare technology operators                               │  │
│   │ ✗ Independent directors with relevant sector experience         │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   ════════════════════════════════════════════════════════════════════  │
│                                                                         │
│   GOVERNANCE STRUCTURE:                                                 │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • Elizabeth Holmes: CEO, Chair, majority voting control         │  │
│   │ • No separate board chair or lead independent director          │  │
│   │ • No audit committee with financial/healthcare expertise        │  │
│   │ • No compensation committee                                     │  │
│   │ • No scientific/technology advisory oversight                   │  │
│   │ • Extreme secrecy; limited information to board                 │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

### Board Effectiveness Failures

| Governance Element | Best Practice | Theranos Reality |
|-------------------|---------------|------------------|
| **Independence** | Majority independent | Founder controlled; no independent oversight |
| **Expertise** | Relevant industry knowledge | Distinguished but irrelevant backgrounds |
| **Committees** | Audit, compensation, nominating | No formal committee structure |
| **Information** | Comprehensive, transparent | Founder controlled all information flow |
| **Challenge** | Constructive skepticism | Prestige used to silence questions |
| **Oversight** | Regular technology/product review | No independent technology validation |
| **CEO evaluation** | Regular, objective assessment | No meaningful CEO oversight |
| **Risk management** | Systematic risk oversight | No enterprise risk assessment |

---

## Governance Failures Analysis

### Failure 1: Board Composition

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    COMPOSITION FAILURE                                  │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   THE PROBLEM:                                                          │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ The board was composed primarily of former government           │  │
│   │ officials and military leaders. While distinguished, they       │  │
│   │ lacked:                                                         │  │
│   │                                                                 │  │
│   │ • Medical device/diagnostics industry experience                │  │
│   │ • Laboratory medicine expertise                                 │  │
│   │ • FDA regulatory experience                                     │  │
│   │ • Healthcare technology operational knowledge                   │  │
│   │ • Ability to evaluate core technology claims                    │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   WHY IT HAPPENED:                                                      │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • Holmes deliberately recruited for prestige, not expertise    │  │
│   │ • Board members lent credibility to fundraising                 │  │
│   │ • Distinguished names attracted media attention                 │  │
│   │ • Military/government ties opened doors to contracts            │  │
│   │ • Prominent directors were less likely to ask tough questions   │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   THE LESSON:                                                           │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ ✓ Boards must include members who can evaluate the core        │  │
│   │   business and technology                                       │  │
│   │ ✓ Prestigious names do not substitute for relevant expertise   │  │
│   │ ✓ Scientific/technology companies need scientific oversight    │  │
│   │ ✓ Diversity of expertise is as important as other diversity    │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

### Failure 2: Founder Control

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    FOUNDER CONTROL FAILURE                              │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   THE PROBLEM:                                                          │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ Elizabeth Holmes maintained complete control through:          │  │
│   │                                                                 │  │
│   │ • Super-voting stock giving her majority control                │  │
│   │ • Combined CEO/Chair role                                       │  │
│   │ • Controlled all board information and agendas                  │  │
│   │ • Romantic relationship with COO (Balwani) undisclosed          │  │
│   │ • Created culture of extreme secrecy                            │  │
│   │ • Intimidated employees who raised concerns                     │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   STRUCTURAL ISSUES:                                                    │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • No independent chair or lead director                         │  │
│   │ • No executive sessions without management                      │  │
│   │ • No direct board access to employees or operations             │  │
│   │ • No independent advisors reporting to board                    │  │
│   │ • Board met infrequently                                        │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   THE LESSON:                                                           │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ ✓ Founder control must be balanced with independent oversight  │  │
│   │ ✓ Board must have independent information sources               │  │
│   │ ✓ Related-party relationships must be disclosed and managed    │  │
│   │ ✓ Executive sessions are essential for candid discussion       │  │
│   │ ✓ Culture of openness enables oversight                        │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

### Failure 3: Lack of Skeptical Inquiry

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    SKEPTICAL INQUIRY FAILURE                            │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   THE PROBLEM:                                                          │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ The board failed to ask fundamental questions:                  │  │
│   │                                                                 │  │
│   │ • Does the technology actually work as claimed?                 │  │
│   │ • Why is there no peer-reviewed scientific validation?          │  │
│   │ • Why can't we see independent test results?                    │  │
│   │ • How do our results compare to standard lab tests?             │  │
│   │ • Why the extreme secrecy even with board members?              │  │
│   │ • Why are employees with concerns being dismissed?              │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   WARNING SIGNS IGNORED:                                                │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ ⚠ Employee departures and complaints                           │  │
│   │ ⚠ No peer-reviewed publications despite claims                 │  │
│   │ ⚠ Extreme secrecy around technology                            │  │
│   │ ⚠ Regulatory challenges with FDA                               │  │
│   │ ⚠ Delayed commercial launches                                  │  │
│   │ ⚠ Scientific advisory board concerns                           │  │
│   │ ⚠ Whistleblower reports                                        │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   THE LESSON:                                                           │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ ✓ Boards must demand evidence, not accept assertions           │  │
│   │ ✓ "Trust but verify" - especially with technology claims       │  │
│   │ ✓ Warning signs and red flags must be investigated             │  │
│   │ ✓ Independent validation of core technology is essential       │  │
│   │ ✓ Whistleblower reports require board attention                │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

### Failure 4: Investor Due Diligence

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    INVESTOR DUE DILIGENCE FAILURE                       │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   THE PROBLEM:                                                          │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ Sophisticated investors invested without:                       │  │
│   │                                                                 │  │
│   │ • Independent technology validation                             │  │
│   │ • Customer reference checks                                     │  │
│   │ • Scientific expert review                                      │  │
│   │ • Regulatory due diligence                                      │  │
│   │ • Management background verification                            │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   INVESTORS INCLUDED:                                                   │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • Rupert Murdoch - $125 million                                 │  │
│   │ • Walgreens - Partnership investment                            │  │
│   │ • Walton Family (Walmart heirs) - $150 million                  │  │
│   │ • Betsy DeVos family - $100 million                             │  │
│   │ • Carlos Slim - Investment                                      │  │
│   │ • Major venture capital firms                                   │  │
│   │                                                                 │  │
│   │ None demanded independent technology validation                 │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   THE LESSON:                                                           │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ ✓ Prestige of other investors is not due diligence             │  │
│   │ ✓ Extraordinary claims require extraordinary evidence          │  │
│   │ ✓ Independent expert validation is essential for tech claims   │  │
│   │ ✓ FOMO (fear of missing out) is not an investment thesis       │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

---

## The Whistleblowers

### Those Who Spoke Up

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    WHISTLEBLOWER EXPERIENCES                            │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   TYLER SHULTZ (George Shultz's grandson):                              │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • Worked at Theranos as lab associate                           │  │
│   │ • Raised concerns internally about inaccurate tests             │  │
│   │ • Reported to his grandfather (board member)                    │  │
│   │ • Was told by grandfather to trust Holmes                       │  │
│   │ • Contacted WSJ and regulators                                  │  │
│   │ • Faced legal threats from Theranos                             │  │
│   │ • Family relationship with grandfather strained                 │  │
│   │ • Spent $400K+ on legal defense                                 │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   ERIKA CHEUNG:                                                         │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • Lab associate who saw quality control problems                │  │
│   │ • Reported concerns internally; was ignored                     │  │
│   │ • Resigned and reported to regulators                           │  │
│   │ • Faced intimidation and legal threats                          │  │
│   │ • Later testified against Holmes                                │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│   GOVERNANCE FAILURE:                                                   │
│   ┌─────────────────────────────────────────────────────────────────┐  │
│   │ • No formal whistleblower channel to the board                  │  │
│   │ • Board member dismissed grandson's concerns                    │  │
│   │ • Company used legal threats to silence critics                 │  │
│   │ • Culture punished dissent                                      │  │
│   │ • Board never investigated employee concerns                    │  │
│   └─────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

---

## Discussion Questions

### Board Composition and Expertise

**Question 1:** Why would distinguished former government officials and military leaders fail to provide effective oversight? What does this suggest about the skills and expertise needed on boards?

**Question 2:** If you were advising a healthcare technology startup on board composition, what specific expertise would you recommend? How would you balance industry expertise with other considerations?

### Founder Dynamics

**Question 3:** How can boards provide effective oversight of charismatic founders who control the company through voting rights? What structural safeguards would you recommend?

**Question 4:** The relationship between Holmes and Balwani (COO) was not disclosed to the board. What policies should govern personal relationships among executives and how should boards verify compliance?

### Information and Verification

**Question 5:** The board relied entirely on Holmes for information about the technology. What independent information sources should a board establish, particularly for technology-intensive companies?

**Question 6:** When should a board insist on independent third-party validation of core technology claims? What role should scientific advisory boards play?

### Whistleblowers and Culture

**Question 7:** George Shultz initially sided with Holmes over his own grandson's concerns. What does this reveal about board dynamics and how personal relationships can impair judgment?

**Question 8:** How should boards establish and monitor whistleblower channels? What cultural indicators should concern a board?

---

## Lessons for Corporate Governance

```
┌─────────────────────────────────────────────────────────────────────────┐
│                    KEY GOVERNANCE LESSONS                               │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│   1. EXPERTISE MATTERS MORE THAN PRESTIGE                               │
│      • Board composition must include relevant industry expertise       │
│      • Big names are not substitutes for capable oversight              │
│      • Technical claims require technically competent directors         │
│                                                                         │
│   2. INDEPENDENCE REQUIRES STRUCTURE                                    │
│      • Founder control must have independent checks                     │
│      • Boards need independent information channels                     │
│      • Executive sessions without management are essential              │
│      • Lead independent director role is critical                       │
│                                                                         │
│   3. VERIFICATION IS ESSENTIAL                                          │
│      • "Trust but verify" is a core board responsibility                │
│      • Extraordinary claims require extraordinary evidence              │
│      • Independent validation of technology is necessary                │
│      • Red flags must be investigated, not explained away               │
│                                                                         │
│   4. CULTURE ENABLES OR PREVENTS OVERSIGHT                              │
│      • Secrecy is a red flag, not a protection                          │
│      • Whistleblower channels must reach the board                      │
│      • Employee concerns deserve investigation                          │
│      • Legal threats to silence critics indicate problems               │
│                                                                         │
│   5. PROCESS PROTECTS                                                   │
│      • Formal committee structures create accountability                │
│      • Regular board evaluation identifies weaknesses                   │
│      • Documented oversight creates accountability                      │
│      • Independent advisors provide external perspective                │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

---

## Governance Checklist: Avoiding a Theranos

Use this checklist to assess governance effectiveness:

| Element | Question | Yes/No |
|---------|----------|--------|
| **Expertise** | Does the board include members who can evaluate core technology/products? | |
| **Independence** | Is there effective independent oversight of the CEO/founder? | |
| **Information** | Does the board have independent sources of information beyond management? | |
| **Validation** | Have core technology claims been independently validated? | |
| **Committees** | Are there functioning audit, compensation, and nominating committees? | |
| **Challenge** | Is constructive challenge encouraged and valued? | |
| **Whistleblower** | Can employees raise concerns directly to the board? | |
| **Red flags** | Are warning signs investigated rather than dismissed? | |
| **Related parties** | Are personal relationships among management disclosed and managed? | |
| **Culture** | Is there a culture of transparency rather than secrecy? | |

---

## Assignment

### Part 1: Board Redesign (10 points)

Design an ideal board for a healthcare technology company similar to Theranos (blood testing startup). Include:

1. Recommended board size and composition
2. Specific expertise requirements (list 5-6 key areas)
3. Committee structure
4. Policies for managing founder control
5. Information channels to the board

### Part 2: Early Warning System (10 points)

Based on the Theranos case, develop an "early warning system" that a board could use to identify potential fraud or governance failures. Include:

1. Five key indicators to monitor
2. Specific information requests the board should make
3. Third-party validations that should be required
4. Red flags that should trigger investigation

### Part 3: Personal Reflection (5 points)

If you were George Shultz, and your grandson raised concerns about the company where you served on the board, how would you handle the situation? What governance principles should guide your response?

---

## Additional Resources

- *Bad Blood: Secrets and Lies in a Silicon Valley Startup* by John Carreyrou
- HBO Documentary: "The Inventor: Out for Blood in Silicon Valley"
- SEC Complaint against Elizabeth Holmes and Theranos
- Trial transcripts and court documents

---

## Next Case

[Case 2: Activist Investor Engagement →](case-02-activist-investor.md)

---

*Case Study 1 | Module 24: Corporate Governance*
